A Lower Viral Set Point but Little Immunological Impact After Early Treatment During Primary HIV Infection

The Primo-SHM trial, a multicenter randomized trial comparing no treatment with 24 or 60 weeks of combination antiretroviral therapy (cART) during primary human immunodeficiency virus (HIV) infection (PHI), recently demonstrated that temporary early cART lowered the viral set point and deferred the...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:Viral Immunol
Asıl Yazarlar: Spits, Hilde B., Grijsen, Marlous L., Steingrover, Radjin, Nanlohy, Nening M., Kootstra, Neeltje, Borghans, José A.M., van Baarle, Debbie, Prins, Jan M., Schellens, Ingrid M.M.
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: Mary Ann Liebert, Inc. 2015
Konular:
Original Research Articles
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC4390083/
https://ncbi.nlm.nih.gov/pubmed/25746670
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1089/vim.2014.0094
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller